Claims
- 1-18. Canceled
- 19. A composition comprising a first component selected from the group consisting of immunostimulants and at least one second component selected from the group consisting of:
(a) sequences comprising at least 20 contiguous residues of the sequence set forth in SEQ ID NO: 431; and (b) sequences comprising at least 20 contiguous residues of the sequence set forth in SEQ ID NO: 577.
- 20. A composition comprising a first component selected from the group consisting of immunostimulants and at least one second component selected from the group consisting of:
(a) sequences having at least 95% identity to the sequence set forth in SEQ ID NO: 431; and (b) sequences having at least 95% identity to the sequence set forth in SEQ ID NO: 571.
- 21. A composition comprising a first component selected from the group consisting of immunostimulants and a second component selected from fusion proteins comprising at least one sequence selected from the group consisting of:
(a) sequences comprising at least 20 contiguous residues of the sequence set forth in SEQ ID NO: 431; and (b) sequences comprising at least 20 contiguous residues of the sequence set forth in SEQ ID NO: 577.
- 22. A composition comprising a first component selected from the group consisting of immunostimulants and a second component selected from fusion proteins comprising at least one sequence selected from the group consisting of:
(a) sequences having at least 95% identity to the sequence set forth in SEQ ID NO: 431; and (b) sequences having at least 95% identity to the sequence set forth in SEQ ID NO: 571.
- 23. A method for stimulating and/or expanding T cells specific for a Chlamydia protein, comprising contacting T cells with at least one component selected from the group consisting of:
(a) sequences comprising at least 20 contiguous residues of the sequence set forth in SEQ ID NO: 431; (b) sequences comprising at least 20 contiguous residues of the sequence set forth in SEQ ID NO: 577. (c) sequences having at least 95% identity to the sequence set forth in SEQ ID NO: 431; and (d) sequences having at least 95% identity to the sequence set forth in SEQ ID NO: 571. under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.
- 24. An isolated T cell population, comprising T cells prepared according to the method of claim 23.
- 25. A method for stimulating an immune response in a patient, comprising administering to the patient a composition according to any one of claims 19-22.
- 26. A method for the treatment of Chlamydia infection in a patient, comprising administering to the patient a composition according to any one of claim 19-22.
- 27. A method for the treatment of Chlamydia in a patient, comprising the steps of:
(a) incubating CD4+ and/or CD8+T cells isolated from a patient with at least one component selected from the group consisting of:
(i) sequences comprising at least 20 contiguous residues of the sequence set forth in SEQ ID NO: 431; (ii) sequences comprising at least 20 contiguous residues of the sequence set forth in SEQ ID NO: 577. (iii) sequences having at least 95% identity to the sequence set forth in SEQ ID NO: 431; and (iv) sequences having at least 95% identity to the sequence set forth in SEQ ID NO: 571. (v) an antigen presenting cell that expresses a polypeptide sequence of (i), (ii), (iii) or (iv), such that the T cells proliferate; and (b) administering to the patient an effective amount of the proliferated T cells.
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent application Ser. No. 09/841,132 filed Apr. 23, 2001; which is a continuation-in-part of U.S. patent application Ser. No. 09/620,412, filed Jul. 20, 2000, now U.S. Pat. No. 6,448,234; which is a continuation-in-part of Ser. No. 09/598,419, filed Jun. 20, 2000, now U.S. Pat. No. 6,565,856; which is a continuation-in-part of U.S. patent application Ser. No. 09/556,877, filed Apr. 19, 2000, now U.S. Pat. No. 6,432,916; which is a continuation-in-part of U.S. patent application Ser. No. 09/454,684, filed Dec. 3, 1999; which is a continuation-in-part of U.S. patent application Ser. No. 09/426,571, filed Oct. 22, 1999, now abandoned; which is a continuation-in-part of U.S. patent application Ser. No. 09/410,568, filed Oct. 1, 1999, now U.S. Pat. No. 6,555,115; which is a continuation-in-part of U.S. patent application Ser. No. 09/288,594, filed Apr. 8, 1999, now U.S. Pat. No. 6,447,779; which is a continuation-in-part of U.S. patent application Ser. No. 09/208,277, filed Dec. 8, 1998, now U.S. Pat. No. 6,166,177, which applications are incorporated herein by reference in their entireties.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09841132 |
Apr 2001 |
US |
Child |
10872155 |
Jun 2004 |
US |
Continuation in Parts (8)
|
Number |
Date |
Country |
Parent |
09620412 |
Jul 2000 |
US |
Child |
09841132 |
Apr 2001 |
US |
Parent |
09598419 |
Jun 2000 |
US |
Child |
09841132 |
Apr 2001 |
US |
Parent |
09556877 |
Apr 2000 |
US |
Child |
09841132 |
Apr 2001 |
US |
Parent |
09454684 |
Dec 1999 |
US |
Child |
09841132 |
Apr 2001 |
US |
Parent |
09426571 |
Oct 1999 |
US |
Child |
09841132 |
Apr 2001 |
US |
Parent |
09410568 |
Oct 1999 |
US |
Child |
09841132 |
Apr 2001 |
US |
Parent |
09288594 |
Apr 1999 |
US |
Child |
09841132 |
Apr 2001 |
US |
Parent |
09208277 |
Dec 1998 |
US |
Child |
09841132 |
Apr 2001 |
US |